Profil Institute Continues to Publish New Findings in Cardiometabolic Research

Profil Institute Continues to Publish New Findings in Cardiometabolic Research

SAN DIEGO, October 11, 2014  Profil Institute for Clinical Research, Inc., an early phase clinical research organization (CRO) focused on diabetes and obesity, in collaboration with its industry and academic partners routinely publishes new findings in cardiometabolic research in peer-reviewed scientific journals. Additionally, Profil Institute authors with academic and industry colleagues have completed a textbook, which will be published late November 2014.  The textbook presents and illustrates research methods for use in early phase clinical studies of new drugs for diabetes, obesity and related cardiometabolic disease.

Recent Articles Published in Scientific Journals:

Several of the more prominent articles published in peer-reviewed scientific journals over the last year are listed below.  Links to the abstracts of these and more 300 other articles published by Profil Institute scientists can be found on the company’s website at

  • Diabetes, Obesity & Metabolism, September 2014 – Albiglutide does not impair the counter-regulatory hormone response to hypoglycemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.
  • PLOS One, August 2014 – Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes.
  • Metabolism: Clinical & Experimental, July 2014 – Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
  • Diabetes, Obesity & Metabolism, June 2014 – Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
  • Diabetes, Obesity & Metabolism, May 2014 – Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes.
  • Diabetes Technology & Therapeutics, May 2014 – Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor.
  • PLOS One, April 2014 – Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
  • Clinical Therapeutics, February 2014 – Pharmacokinetic and Pharmacodynamic Responses of Insulin Degludec in African American, White, and Hispanic/Latino Patients With Type 2 Diabetes Mellitus.
  • Journal of Diabetes Science and Technology, January 2014 – Biosimilar Insulins: Basic Considerations.
  • Drugs, October 2013 – Targeting hyperglycaemia with anti-obesity drugs: time for a paradigm shift.
  • Diabetes Care, October 2013 – Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes.

Forthcoming Textbook:

The textbook, Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development, is in production with publisher Springer and begins shipping late November 2014. It will be the first textbook to extensively analyze and illustrate techniques for use in early phase clinical studies of new drugs for diabetes, obesity and related cardiometabolic disease.  Each chapter focuses on a specific approach or methodology, written by a leading expert providing practical applications and scrutinizing pros and cons.  Authors include scientists from Profil Institute, as well as renowned scientists from University of Florida; Maastricht University Medical Centre; Deutsches Forschungszentrum für Gesundheit und Umwelt; Image Reading Center, Inc.; Kinexum, Inc.; Kinmed, Inc.; National Institutes of Health; and University of California, San Diego.

“At Profil Institute we are in a unique position of having been involved in the clinical investigation of every clinically relevant diabetes drug class, as well as nearly all modes of administration and blood glucose monitoring devices.  With this expertise comes the privilege and responsibility to contribute to scientific research in the public domain.  We take great pride in the contributions we’ve made to benefit diabetes research and that are applied to finding new treatments for cardiometabolic disorders,” said Dr. Marcus Hompesch, Profil Institute President and CEO.

About Profil Institute for Clinical Research, Inc.

Profil Institute for Clinical Research, Inc. is a science driven, early phase clinical research organization (CRO) focused on diabetes and obesity.  It is renowned for its scientific expertise, depth of services, expanded scope of research methodologies, and experience with every clinically relevant drug class in diabetes.  The company provides end-to-end early phase services from consulting for strategic clinical development and regulatory planning through design and completion of complex clinical trials, including the reporting and publication of final study results.

Profil Institute’s expertise and experience encompasses small and large molecule therapies, biologics and biosimilars through all routes of administration, as well as devices.  The company’s clients range from large pharma and drug discovery companies to small virtual companies throughout the Americas, Europe and Asia.

Profil Institute is also recognized internationally as an innovator of methodologies to improve the quality of metabolic research, including its Automated Glucose Clamp technology.  As the leading early phase CRO focused on diabetes and obesity, Profil Institute is driving new, higher standards in metabolic clinical research through collaborative science with key academic and industry partners  and its Metabolic Research Partners™ program.

Please visit

For further information, please contact:
Abby Devine
Corporate Communications